TOP10 reimbursement value in Poland – October 2024

?? Updated October 2024 #DGL bulletin data

?? In October 2024, the cumulative #reimbursement amount stands at PLN 19.7 billion, which is 4 billion more than in the same period of the previous year. It is worth to mention that the total reimbursement amount in 2023 was 20 billon and we almost reach that point in October 2024.

?? The ranking of the top ten products across the entire market has remained stable. #Spinraza has seen another decline, now occupying 6th position after switching places with #Darzalex.

?? In the drug programmes, #Darzalex has risen to third place in the rankings, achieving a cumulative reimbursement total of 255 million this year, reflecting a 60% increase compared to the same period last year.

?? On the outpatient list, #Trulicity dropped two places to 9th position, while #Atoris and #Contour moved up to 7th and 8th positions, respectively – with Contour advancing despite a year-over-year decline in reimbursement of -4.1%.

You can find more data in our IDA TOP10 report: https://app.powerbi.com/view?r=eyJrIjoiZGI3MDlkYWEtZDhmZi00MmIxLTlkNDctZTk3NjgyZWQyMjUyIiwidCI6IjFhYjJiNGUwLWE4ZmUtNGQ3OS1hY2Q1LTk2NzhlMThiN2IxOSIsImMiOjl9&embedImagePlaceholder=true